Tell Your Story
Create a world without ALS. Speak up now to give hope. Tell your story about ALS and what you hope for…
View and share other stories of hope
Phase III Dex Trial Discussion
Early this year, The ALS community was saddened by the results of Biogen’s phase III clinical trial of dexpramipexole and disappointed in the company’s announcement that it will discontinue development of the drug. Was there any good news to come out of the trial?
The ALS Association’s Chief Scientist Lucie Bruijn spoke with Biogen’s Douglas Kerr, M.D., Ph.D., Director of Neurodegeneration, Clinical Research, about the company’s ongoing commitment to ALS and how this trial does in fact contribute to the search for treatments and a cure for Lou Gehrig’s disease.
Click play to listen to their conversation:
Read more about dexpramipexole: http://www.alsa.org/news/media/press-releases/biogen-discontinues-dexpram.html
Related News
Call for Proposals for Phase II Clinical Trials from MGH Neurological Clinical Research Institute and The ALS Association
ALS Association’s Drug Company Working Group Discusses Dexpramipexole, Tirasemtiv and Biomarkers
Study Published in Nature Neuroscience Finds Spinal Cord Cells That Normally Support Neurons Worsen ALS
Study Involving Injection of Antisense Molecules into Spinal Cord Area of People with Lou Gehrig’s Disease Is Safe
The ALS Association - 1275 K Street NW - Suite 1050 - Washington, DC 20005
All content and works posted on this website are owned and copyrighted by The ALS Association. ©2013
